Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead MarketBeat - Mon Jun 8, 12:03PM CDT

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions...

ASMB : 24.44 (+1.20%)
MarketBeat.com
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands MarketBeat - Fri Jun 5, 2:03PM CDT

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications,...

ASMB : 24.44 (+1.20%)
Assembly Biosciences Announces Upcoming Investor Conference Presentations GlobeNewswire - Thu May 28, 3:05PM CDT

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 24.44 (+1.20%)
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Tue May 26, 3:05PM CDT

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 24.44 (+1.20%)
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Fri May 22, 6:05AM CDT

SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 24.44 (+1.20%)
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases GlobeNewswire - Fri May 22, 6:00AM CDT

– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN...

ASMB : 24.44 (+1.20%)
MarketBeat.com
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference MarketBeat - Thu May 14, 6:05AM CDT

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing...

ASMB : 24.44 (+1.20%)
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 GlobeNewswire - Wed May 13, 1:00AM CDT

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today...

ASMB : 24.44 (+1.20%)
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference GlobeNewswire - Mon May 11, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today...

ASMB : 24.44 (+1.20%)
Assembly Biosciences: Q1 Earnings Snapshot AP - Thu May 7, 3:08PM CDT

Assembly Biosciences: Q1 Earnings Snapshot

ASMB : 24.44 (+1.20%)

Barchart Exclusives

Microsoft vs. Nvidia: Which AI Giant Is the Better Dividend Stock for the Long Haul? Barchart - 1 hour ago
Microsoft and NVIDIA are AI giants, but which stock is the better buy? Compare growth, valuation, dividends, and Wall Street ratings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.